Hard to Treat Diseases, Inc. (HTDS) TO Appoint Prof Mirjana Stojiljkovic As A Medical Advisor - Company Officer

Friday, September 18, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

BELGRADE, SERBIA, July 29 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com announced today that it will shortly appoint Prof Mirjana Stojiljkovic as a Medical Advisor to HTDS.

Prof Mirjana Stojiljkovic is a well respected scientist. Prof Stojiljkovic leads a group of researchers from Department of Neurobiology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Serbia, (IBISS group). The group introduced a novel therapeutic approach in treatment of multiple sclerosis (MS), a severe, currently incurable, human disease. The effectiveness of this therapy is shown in experimental animals and has to be proven in people with MS, so that obtained results has to be considered as "experimental." Experimental data obtained on laboratory animals provide the following beneficial effects of the therapy:

The appointment will effectively take place after the review of the current Adequate Disclosure filed with Pink Sheets, and will be reflected in the issuer's next quarterly Adequate Disclosure filing update. The issuer has heard back from Pink Sheets on its original Adequate Disclosure submission. The company's barrister is currently complying with the requests made by the Pink Sheets review staff. The company expects to be in full compliance and to obtain the highest tier ranking of Pink Sheets with the "Current Information" ranking. See: http://www.pinksheets.com/pink/otcguide/investors_market_tiers.jsp shortly.

Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer of HTDS said "The appointment of Prof Mirjana Stojiljkovic to HTDS will be a great asset to our whole organization. We have requested to meet our corporate advisors here in Belgrade in mid August, and representatives of Mellow Hope www.mellowhope.com (Mellow Hope is a China based second operating subsidiary of HTDS in the business of vaccine distribution) to amongst other things discuss appointments and expanded role of other medical professionals to the HTDS board. We will also start working on a new web site for Slavica Bio Chem and HTDS Medical as well. On the operational updates and something we will do from time to time to keep our followers advised of our progress, and just to keep in touch; our newest young scientist Dr. Ivana Gadjanski, Communication Director Chief Liaison who just joined our team will attend the The International Summer School, Piran, Slovenia, August 21 - 29, 2009 on stem cells and regenerative medicine.


The International Summer School, Piran, Slovenia, August 21 - 29, 2009 is a PhD-level course for graduate students in life sciences focusing on advanced approaches to isolation, characterization and differentiation of stem cells. The aim is to introduce the students to different aspects of stem cell research and development of new strategies for their clinical applications. The course is covering a wide range of topics, starting with the problem of selection of stem cell source, ethical and legislative issues, followed by laboratory scale systems and engineering, and ending with translation to clinics."

The company invites any inquiries from qualified medical professionals to contact Dr. Ivana Gadjanski, medicalinfo@htdsmedical.com, regarding the MS and CNS progress and reports.

The company intends to provide further updates shortly, and a brief CEO statement from Mr Terry Yuan, HTDS CEO, and which will include the issuers forward guidance.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com

- The severity of clinical signs of disease was significantly reduced - The pathological changes in the myelin sheath (demyelination) were not detected - The reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia was observed in the spinal cord tissue - The degree of disability was lowered - The duration of the disease was notably shortened - The percentage mortality in severe disease was radically reduced (70%) - The severity of treatment side effects was low and disappeared after cessation of drug application

SOURCE Hard to Treat Diseases

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store